HomeAI · summaries
Storia in 2 fonti
Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), alb | After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), albeit with revised safety precautions tucked into the product packaging.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Amgen stands by Tavneos, despite reports of 20 deaths in Japan
The FDA wants Amgen's Tavneos off the market. European regulators are investigating data-integrity concerns. And now, a pharma selling the drug in Japan is warning doctors against…
- ·
fiercepharma.com
Amgen's Tavneos, facing liver injury scrutiny, gets label update in Japan as patient starts resume
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med…
- ·
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire…
- ·
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
The TROP2 battle in first-line triple-negative breast cancer has officially kicked off. | A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is…